Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Narlumosbart - CSPC Pharmaceutical Group

Next Previous
X
Search
Drug Profile

Narlumosbart - CSPC Pharmaceutical Group

Alternative Names: Anti-RANKL monoclonal antibody - CSPC Pharmaceutical Group; Jinlitai; JMT-103; Narlumosbart - Shanghai Jinmante Biotechnology

Latest Information Update: 20 Jul 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yong Shun Technology Development
  • Developer CSPC Pharmaceutical Group; Shanghai Jinmante Biotechnology
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action RANK ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Giant cell tumour of bone
  • Phase II Bone metastases; Postmenopausal osteoporosis
  • Discontinued Malignant hypercalcaemia

Most Recent Events

  • 31 May 2024 Efficacy and adverse events data from a phase Ib trial in Bone metastases presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 01 Feb 2024 Shanghai JMT-Bio plans a phase III trial for Bone metastases in China [SC,Injection] in April 2024 (NCT06221072)
  • 13 Oct 2023 Discontinued - Clinical-Phase-Unknown for Malignant hypercalcaemia in China (SC) prior to October 2023 (CSPC Pharmaceuticals pipeline, October 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top